The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrinc tumor receiving everolimus plus somatostatin analog treatment

被引：1
|
作者：
Pusceddu, Sara
Buzzoni, Roberto
Giacomelli, Luca
Mazzaferro, Vincenzo
Concas, Laura
Mllione, Massimo
Formisano, Barbara
D'Autilla, Elise
Festinese, Fabrizio
De Braud, Filippo G.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Natl Canc Inst, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15172
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Impact of Prior Somatostatin Analogue (SSA) Use on Progression-Free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
    Buzzoni, R.
    Carnaghi, C.
    Pommier, R.
    Fazio, N.
    Singh, S.
    Voi, M.
    Pacaud, L.
    Ridolfi, A.
    Yao, J.
    Wolin, E.
    Pavel, M.
    Strosberg, J.
    NEUROENDOCRINOLOGY, 2016, 103 : 79 - 79
  • [42] Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM study
    McArthur, G.
    Larkin, J.
    Dreno, B.
    Ascierto, P.
    Liszkay, G.
    Maio, M.
    Mandala, M.
    Demidov, L.
    Stroyakovskiy, D.
    Thomas, L.
    De la Cruz-Merino, L.
    Atkinson, V.
    Dutriaux, C.
    Garbe, C.
    Wongchenko, M.
    Hsu, J.
    Koralek, D.
    Rooney, I.
    Yan, Y.
    Ribas, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S722 - S723
  • [43] ENUMERATION CIRCULATING TUMOR CELLS (CTCS) IS A PROGNOSTIC AND PREDICTIVE FACTOR FOR PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN COLON CANCER PATIENTS RECEIVING FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB. A TTD SPANISH GROUP COOPERATIVE STUDY
    Sastre, J.
    Maestro, M. L.
    Gomez, M. A.
    Rivera Herrero, F.
    Valladares, M.
    Massuti, B.
    Gallen, M.
    Benavides, M.
    Diaz Rubio, E.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 67
  • [44] Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC).
    Solomon, Benjamin J.
    Bauer, Todd Michael
    Felip, Enriqueta
    Liu, Geoffrey
    Mazieres, Julien
    De Marinis, Filippo
    Goto, Yasushi
    Kim, Dong-Wan
    Laktionov, Konstantin K.
    Blackhall, Fiona Helen
    Dall'O, Elisa
    Polli, Anna
    Toffalorio, Francesca
    Mok, Tony S. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK plus non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
    Solomon, Benjamin J.
    Liu, Geoffrey
    Felip, Enriqueta
    Mok, Tony S. K.
    Soo, Ross Andrew
    Mazieres, Julien
    Shaw, Alice Tsang
    de Marinis, Filippo
    Goto, Yasushi
    Wu, Yi-Long
    Kim, Dong-Wan
    Martini, Jean-Francois
    Messina, Rossella
    Paolini, Jolanda
    Polli, Anna
    Thomaidou, Despina
    Toffalorio, Francesca
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8503 - LBA8503
  • [46] Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
    Bachelot, T.
    Royce, M.
    Villanueva, C.
    Melo Cruz, F.
    Hegg, R.
    Falkson, C.
    Jeong, J.
    Srimuninnimit, V.
    Arce, C. H.
    Ridolfi, A.
    Lin, C.
    Gradishar, W.
    Ozguroglu, M.
    Cardoso, F.
    Azevedo, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Analysis of Progression-Free Survival (PFS) by Prior Chemotherapy Use and Updated Safety in RADIANT-3: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Everolimus in Patients with Advanced Low- or Intermediate-Grade Pancreatic Neuroendocrine Tumors (pNET)
    Hobday, Timothy
    Pommier, Rodney
    Van Cutsem, Eric
    Panneerselvam, Ashok
    Saletan, Stephen
    Winkler, Robert E.
    Yao, James C.
    PANCREAS, 2012, 41 (02) : 345 - 345
  • [48] On-treatment (tx) dynamic circulating tumor DNA changes (ΔctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER22 advanced breast cancer (ABC) in MONALEESA-3 (ML-3)
    Chia, Stephen K. L.
    Solovieff, Nadia
    Joshi, Mukta
    Im, Seock-Ah
    Bianchi, Giulia Valeria
    de la Cruz-Merino, Luis
    Jerusalem, Guy Heinrich Maria
    Sonke, Gabe S.
    Nusch, Arnd
    Beck, J. Thaddeus
    Slamon, Dennis J.
    Wang, Craig
    Zarate, Juan Pablo
    Su, Fei
    Neven, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial
    Verzoni, Elena
    Bracarda, Sergio
    Ricci, Sergio
    Sacco, Cosimo
    Ridolfi, Laura
    Porta, Camillo
    Miceli, Rosalba
    Zilembo, Nicoletta
    Bajetta, Emilio
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study
    Mori, Shoma
    Maiguma, Takayoshi
    Yoshii, Keisuke
    Moriya, Yasushi
    Takada, Ryo
    Shinkai, Fumitaka
    Haruki, Yuto
    Hashimoto, Hikari
    Komoto, Atsushi
    Takayanagi, Kazunobu
    Tamura, Koji
    Okura, Yusuke
    Sugiyama, Tetsuhiro
    Shimada, Kenichi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (08):
12345